Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism

Histone deacetylase (HDAC) inhibitors prevent neural cell death in in vivo models of cerebral ischaemia, brain injury and neurodegenerative disease. One mechanism by which HDAC inhibitors may do this is by suppressing the excessive inflammatory response of chronically activated microglia. However, the molecular mechanisms underlying this anti‐inflammatory effect and the specific HDAC responsible are not fully understood. Recent data from in vivo rodent studies have shown that inhibition of class I HDACs suppresses neuroinflammation and is neuroprotective. In our study, we have identified that selective HDAC inhibition with inhibitors apicidin, MS‐275 or MI‐192, or specific knockdown of HDAC1 or 2 using siRNA, suppresses the expression of cytokines interleukin‐6 (IL‐6) and tumour necrosis factor‐alpha (TNF‐α) in BV‐2 murine microglia activated with lipopolysaccharide (LPS). Furthermore, we found that in the absence of HDAC1, HDAC2 is up‐regulated and these increased levels are compensatory, suggesting that these two HDACs have redundancy in regulating the inflammatory response of microglia. Investigating the possible underlying anti‐inflammatory mechanisms suggests an increase in protein expression is not important. Taken together, this study supports the idea that inhibitors selective towards HDAC1 or HDAC2, may be therapeutically useful for targeting neuroinflammation in brain injuries and neurodegenerative disease.

[1]  F. Ge,et al.  Acetylome Analysis Reveals Diverse Functions of Lysine Acetylation in Mycobacterium tuberculosis* , 2014, Molecular & Cellular Proteomics.

[2]  D. Chuang,et al.  HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. , 2014, American journal of translational research.

[3]  C. Lowenstein,et al.  Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen‐activated protein kinase phosphatase‐1 , 2014, Journal of leukocyte biology.

[4]  H. Boddeke,et al.  Histone deacetylase inhibitors suppress immune activation in primary mouse microglia , 2013, Journal of neuroscience research.

[5]  Benjamin E. L. Lauffer,et al.  Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability , 2013, The Journal of Biological Chemistry.

[6]  S. Cowley,et al.  The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. , 2013, Biochemical Society transactions.

[7]  H. Schluesener,et al.  Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. , 2013, Journal of neuropathology and experimental neurology.

[8]  O. Dovey,et al.  Histone deacetylase (HDAC) 1 and 2 are essential for normal T cell development and genomic stability in mice , 2013, Clinical Epigenetics.

[9]  R. Grigg,et al.  Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. , 2012, Leukemia research.

[10]  Cristina Viéitez,et al.  Modelling Neuroinflammation In Vitro: A Tool to Test the Potential Neuroprotective Effect of Anti-Inflammatory Agents , 2012, PloS one.

[11]  Dorte B. Bekker-Jensen,et al.  Proteomic Analysis of Lysine Acetylation Sites in Rat Tissues Reveals Organ Specificity and Subcellular Patterns , 2012, Cell reports.

[12]  K. Hensley,et al.  A comparative review of cell culture systems for the study of microglial biology in Alzheimer’s disease , 2012, Journal of Neuroinflammation.

[13]  Jianhua Li,et al.  Neuroprotective effects of valproic acid following transient global ischemia in rats. , 2012, Life sciences.

[14]  Fu-qian He,et al.  Tetrandrine suppresses amyloid-β-induced inflammatory cytokines by inhibiting NF-κB pathway in murine BV2 microglial cells. , 2011, International immunopharmacology.

[15]  K. Ogawa,et al.  Histone deacetylase inhibitors block nuclear factor‐κB‐dependent transcription by interfering with RNA polymerase II recruitment , 2011, Cancer science.

[16]  L. Kenner,et al.  Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis , 2011, Cell cycle.

[17]  E. Shohami,et al.  Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries , 2011, Molecular medicine.

[18]  Ya-Li Yao,et al.  Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates , 2010, Journal of biomedicine & biotechnology.

[19]  H. Schluesener,et al.  MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis , 2010, Neuroscience.

[20]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[21]  Sunhee C. Lee,et al.  Histone Deacetylase Inhibitors Suppress the Expression of Inflammatory and Innate Immune Response Genes in Human Microglia and Astrocytes , 2010, Journal of Neuroimmune Pharmacology.

[22]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[23]  M. Hottiger,et al.  Acetylation of p65 at lysine 314 is important for late NF-κB-dependent gene expression , 2010, BMC Genomics.

[24]  A. Chiarugi,et al.  Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo , 2009, Neurobiology of Disease.

[25]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[26]  J. Deleo,et al.  Differential migration, LPS‐induced cytokine, chemokine, and NO expression in immortalized BV‐2 and HAPI cell lines and primary microglial cultures , 2008, Journal of Neurochemistry.

[27]  A. Kozikowski,et al.  HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats , 2008, Brain Research.

[28]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[29]  P. Gean,et al.  Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity , 2007, Neuroscience.

[30]  M. Lew,et al.  Good statistical practice in pharmacology Problem 2 , 2007, British journal of pharmacology.

[31]  T. Beckers,et al.  Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group , 2007, International journal of cancer.

[32]  D. Chuang,et al.  Histone Deacetylase Inhibitors Exhibit Anti-Inflammatory and Neuroprotective Effects in a Rat Permanent Ischemic Model of Stroke: Multiple Mechanisms of Action , 2007, Journal of Pharmacology and Experimental Therapeutics.

[33]  J. Roh,et al.  Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation , 2007, Neurobiology of Disease.

[34]  A. Guidotti,et al.  The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Nitsch,et al.  The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells , 2006, Neuron.

[36]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[37]  G. Stephanopoulos,et al.  Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[38]  D. Chuang,et al.  Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. , 2005, Brain research. Molecular brain research.

[39]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Greene,et al.  Regulation of NF-κB action by reversible acetylation , 2004 .

[41]  W. Greene,et al.  Shaping the nuclear action of NF-κB , 2004, Nature Reviews Molecular Cell Biology.

[42]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[43]  S. Kyrylenko,et al.  Regulation of microglial inflammatory response by histone deacetylase inhibitors , 2003, Journal of neurochemistry.

[44]  B. Schuettengruber,et al.  Autoregulation of Mouse Histone Deacetylase 1 Expression , 2003, Molecular and Cellular Biology.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[47]  V. Ogryzko,et al.  Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.

[48]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[49]  H. Kettenmann,et al.  An immortalized cell line expresses properties of activated microglial cells , 1992, Journal of neuroscience research.

[50]  F. Bistoni,et al.  Immortalization of murine microglial cells by a v-raf / v-myc carrying retrovirus , 1990, Journal of Neuroimmunology.

[51]  T. R. Hebbes,et al.  A direct link between core histone acetylation and transcriptionally active chromatin. , 1988, The EMBO journal.

[52]  Marcel Leist,et al.  The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. , 2009, ALTEX.

[53]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[54]  W. Greene,et al.  Regulation of NF-kappaB action by reversible acetylation. , 2004, Novartis Foundation symposium.

[55]  W. Greene,et al.  Shaping the nuclear action of NF-kappaB. , 2004, Nature reviews. Molecular cell biology.